SCHEDULE 13G/A: Bio-Rad Laboratories Maintains Significant 9.66% Stake in Oncocyte Corporation
Beneficial Ownership Disclosure Amendment
Bio-Rad Laboratories, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.66% of Oncocyte Corporation's common shares as of February 10, 2025.
Summary
- Bio-Rad Laboratories, Inc. (the "Reporting Person") has filed an Amendment No. 2 to Schedule 13G concerning its beneficial ownership in Oncocyte Corporation.
- As of February 10, 2025, Bio-Rad Laboratories beneficially owns 2,764,078 Common Shares of Oncocyte Corporation.
- This ownership represents 9.66% of Oncocyte Corporation's total outstanding Common Shares.
- The percentage calculation is based on 28,599,285 outstanding Common Shares of Oncocyte Corporation as of the event date, a figure provided by the Issuer.
- Bio-Rad Laboratories holds sole voting power and sole dispositive power over all 2,764,078 shares, with no shared voting or dispositive power.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics, into Oncocyte Corporation, a company operating in the precision diagnostics space. Such an investment by a larger industry player could signal confidence in Oncocyte's market position or future prospects within the broader healthcare and biotechnology sectors, though the filing itself does not provide strategic rationale.
Stakeholder Impact
- Shareholders of Oncocyte Corporation are informed of Bio-Rad Laboratories' continued significant beneficial ownership stake, which could be interpreted as a sign of long-term interest from a strategic investor.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 03/04/2025 | Date of signing of the Schedule 13G Amendment No. 2. |
Keywords
Oncocyte Corporation, Bio-Rad Laboratories, SEC filing, Schedule 13G, beneficial ownership, equity stake, common shares, investment, healthcare, biotechnology, diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.